Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway

Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with <5% five-year survival rate due to late diagnosis, limited treatment options and chemoresistance. There is thus an urgent unmet clinical need to develop effective anticancer drugs to treat pancreatic cancer. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Wu, Xingye, Zhang, Zhonglin, Ma, Chao, Wu, Tingting, Tang, Shengli, Zeng, Zongyue, Huang, Shifeng, Gong, Cheng, Yuan, Chengfu, Zhang, Linghuan, Feng, Yixiao, Huang, Bo, Liu, Wei, Zhang, Bo, Shen, Yi, Luo, Wenping, Wang, Xi, Liu, Bo, Lei, Yan, Ye, Zhenyu, Zhao, Ling, Cao, Daigui, Yang, Lijuan, Chen, Xian, Haydon, Rex C., Luu, Hue H., Peng, Bing, Liu, Xubao, He, Tong-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297164/
https://www.ncbi.nlm.nih.gov/pubmed/30559409
http://dx.doi.org/10.1038/s41598-018-36214-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297164/
https://www.ncbi.nlm.nih.gov/pubmed/30559409
http://dx.doi.org/10.1038/s41598-018-36214-5

Ejemplares similares